1)Bijie H, et al:In vitro activity, pharmacokinetics, clinical efficacy, safety and pharmacoeconomics of ceftriaxone compared with third and fourth generation cephalosporins;Review. J Chemother 17:3-24, 2005
2)Vesteinsdottir I, et al:Risk factors for Clostridium difficile toxin-positive diarrhea;A population-based prospective case-control study. Eur J Clin Microbiol Infect Dis 31:2601-2610, 2012
3)Paterson DL, et al:International prospective study of Klebsiella pneumoniae bacteremia;Implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med 140:26-32, 2004
4)Washio M, et al:Risk factors for methicillin-resistant Staphylococcus aureus(MRSA)infection in a Japanese geriatric hospital. Public Health 111:187-190, 1997
5)Rubin LG, Schaffner W:Clinical practice. Care of the asplenic patient. N Engl J Med 371:349-356, 2014
6)Andrews MM, von Reyn CF:Patient selection criteria and management guidelines for outpatient parenteral antibiotic therapy for native valve infective endocarditis. Clin Infect Dis 33:203-209, 2001
7)Duncan CJ, et al:Outpatient parenteral antimicrobial therapy with ceftriaxone, a review. Int J Clin Pharm 34:410-417, 2012
8)Hase R, et al:The first trial of OPAT(outpatient parenteral antimicrobial therapy)with continuous infusions in Japan. Kansenshogaku Zasshi 88:269-274, 2014